"FINANCING-TO-DATE The Company has secured more than $3 million to fund its vaccine development and operations. Most of the financing has come from Connecticut Innovations ( www.ctinnovations.com), followed by G. P. Healthcare ( www.gerpanghealthcare.com), Shandong Province, China; and from non-dilutive funding sources such as grants and awards."
Mr. Fengyou (Frank) Lu is a pharmaceutical leader with significant experience in medical product marketing, planning, new product launch, market management, marketing team management, and marketing agent network building in China for over 20 years.
Currently, Mr. Lu is the Chairman, President & CEO of Shandong Gerpang Healthcare Biotechnology Group Co., Ltd (http://www.gerpanghealthcare.com) a pharmaceutical conglomerate in Shandong, China. Mr Lu is also President of GP Fortune Investment LLC and Chairman of SOTA Biomedical Investment Inc., in Toronto, Canada. He also served as CEO of MeiDaKang Pharmaceutical Co. Ltd; General Manager of Linuo Kelong Pharmaceutical Co. Ltd; General Manager of Quangang Biological Pharmaceutical Co. Ltd; and Regional Manager/Chief of Sales of Health Vision HK Ltd. In recent years, Mr. Lu has invested in medical technology companies, including in North America and has established multi-level partnerships with academia, including McGill University, University of Toronto, and MaRS Discovery District in Toronto, one of the world's largest urban innovation hubs. Mr. Lu has been appointed Visiting Professor of the Department of Pharmacology in Shandong Wanje Medical School, Jinan, PR China. He has published 20 scientific papers in cardiovascular and cerebrovascular diseases, HBV-related diseases, stem cell therapy, genetic and reproductive systems.
Mr. Lu holds a Master of Pharmacology and a Bachelor of Pharmacology degrees from the School of Pharmacy, Shandong University.
Market Data 
Markets 
AI
